Zimmer Biomet Holdings, Inc (NYSE: ZBH) is a medical device company that designs, manufactures, and sells reconstructive orthopedic implants and related surgical products. Revenue is generated through transactional sales of implants and instruments to hospitals and surgical facilities, with surgeons and healthcare systems as the primary customers. The company operates across knees, hips, shoulders, elbows, and other joints, and competes in the global orthopedic reconstruction market. The 10-K filed 2026-02-20 (accession 000119312526059853) identifies competition, pricing pressures, dependence on new product development, and shifts in product category and regional sales mix as material business risks, consistent with a transactional implant business where product cycles and hospital contracting drive revenue. The filing also flags customer demand changes driven by demographic shifts as a demand driver, pointing to aging populations as a key end-market tailwind. Zimmer Biomet is incorporated in the United States and headquartered in Warsaw, Indiana.
Reconstructive orthopedic implants for knees, hips, shoulders, elbows, and other joints; surgical instruments and related products. The filing references a product portfolio rationalization plan as of the FY2025 10-K (filed 2026-02-20).
Transactional sales of orthopedic implants, instruments, and related products to hospitals and surgical facilities. Revenue varies by product category mix and regional geography, as noted in the FY2025 10-K (filed 2026-02-20).
Hospitals, surgical facilities, and surgeons. End market demand is tied to orthopedic reconstruction procedures, with demographic changes identified as a driver of customer demand in the FY2025 10-K (filed 2026-02-20).
The FY2025 10-K (filed 2026-02-20) references regional sales mix as a factor affecting results, indicating multi-geographic operations, but specific country or segment revenue breakdowns are not supported by the provided excerpts.
Loading...